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Abstract
Aim—To determine if the drug doses and administration schedules of carboplatin and 
gemcitabine combination affect antitumor effects.
Materials and Methods—The inhibition of cell viability was measured by MTT assay. Median 
effect analysis was conducted to determine the cytotoxicity activity of carboplatin and 
gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.
Results—Synergism was observed when the bladder cancer cell line 5637 cells were treated with 
gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate 
antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell 
cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.
Conclusions—Different doses and administration schedules affect the anti-tumor effect of 
carboplatin/gemcitabine combination that may have clinical significance in the treatment for 
bladder cancer.
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The platinum/gemcitabine combination and MVAC (methotrexate, vinblastine, adriamycin 
and cisplatin) are the two first-line regimens with similar anti-tumor efficacy in the 
treatment of metastatic bladder transitional cell carcinoma (TCC) (1). Because of the 
significant toxicity associated with MVAC, the combination of platinum/gemcitabine has 
largely replaced MVAC and become the first-line chemotherapy regimen for bladder cancer. 
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Carboplatin is a second-generation platinum analog. Compared with the first-generation 
cisplatin, carboplatin has milder toxicity profile with less nephrotoxicity and neurotoxicity. 
This is especially appealing in bladder cancer as many of these patients have renal 
insufficiency and cardiovascular co-morbidities that precludes them from using cisplatin. 
Cisplatin or carboplatin in combination with gemcitabine has also been widely used in many 
other cancer types (2–5). Gemcitabine may provide a survival benefit in some platinum-
resistant cancer cases because of the different mechanisms of action (6). Several studies 
have analyzed the anti-tumor activity of carboplatin/gemcitabine combination with 
contradicting results (7–10). This study performed a systemic analysis to determine how the 
doses and administration schedules of carboplatin/gemcitabine combination affect its anti-
tumor effects and correlate with the underlying mechanisms in a bladder cancer cell line.
Materials and Methods
Chemicals
Gemcitabine (GEMZAR®) was obtained from Eli Lilly (Indianapolis, IN, USA), carboplatin 
(CARBOplatin®, 10 mg/ml) from Hospira (Lake Forest, IL, USA). Thiazolyl Blue 
Tetrazolium Bromide (MTT) and Propidium iodide (PI) was obtained from Sigma (Saint 
Louis, MO, USA). RPMI-1640 Medium was obtained from ATCC (Manassas, VA, USA). 
A human urinary bladder TCC cell line 5637 was obtained from ATCC (Manassas, VA, 
USA). The cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine 
serum, 2 µM L-glutamine and 1% penicillin/streptomycin.
Growth inhibition tests
The MTT assay was performed to determine the growth inhibition (11). In brief, 5637 cells 
at 4000 cells/well were seeded in 96-well plates. After overnight culture, cells were treated 
with carboplatin and/or gemcitabine. When cells were treated with carboplatin alone, they 
were treated for 4 h to mimic the in vivo half-life of carboplatin of 1.3–6 h (12,13). The 
following combinations were tested: (i) 4 h gemcitabine followed by 4 h carboplatin; (ii) 0.5 
h carboplatin followed by 3.5 h carboplatin plus gemcitabine; (iii) 4 h carboplatin followed 
by 4 h gemcitabine. In Group ii, the treatment schedule was designed to mimic the clinical 
administration of carboplatin followed by gemcitabine infusion in patients. After these 
treatments, the cells were washed and cultured with complete medium at 37°C for 68 h in a 
humidified atmosphere containing 5% CO2. After treatment with MTT, the absorption was 
measured at 570 nm and 690 nm using a SpectraMax M2 microplate reader (Molecular 
Devices, Sunnyvale, CA, USA). The percentage of viable cells was calculated using the 
formula (14): % living cells = (sample ext. − blank ext.) / (control ext.− blank ext.) where 
ext.= extinction of the purple color measured at 570 nm − that measured at 690 nm. The 
IC50 (the concentration required for 50% inhibition) was calculated using the GraphPad 
Prism 5 program (GraphPad Software Inc., San Diego, CA, USA). Each drug or 
combination was tested at least in triplicate.
Median effect analysis
This method proposed by Chou and Talalay was used to determine the nature (synergism, 
additivity and antagonism) of drug and drug interaction (15,16). The drugs were combined 
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in the same concentration ratio based on their corresponding IC50s (carboplatin : 
gemcitabine = 289.30 µM: 0.086 µM = 3364:1). This method, termed as the combination 
index (CI) equation, allows quantitative determinations of drug interactions at increasing 
levels of cell kill (Figure 1 and Tables I and II). The CI value allows the classification of the 
anti-tumor activity of the drug combination (Table I). Dm is the antilog of x-intercept, 
meaning the concentration of carboplatin, gemcitabine, or in combination needed to induce 
50% of cell killing. Fa is the fraction of cell death induced by drug treatment. It ranges from 
0–1, with the Fa value of 0 meaning no cell killing and the value of 1 representing 100% of 
cell killing. The 5637 cells were treated with serial dilutions of each drug alone or with 
carboplatin/gemcitabine combination at a fixed ratio of 3364:1. Five dilutions ranging from 
one fourth of the IC50 to four times of the IC50 concentrations (serial dilution factor = 2) of 
each drug, in combination plus a control were tested in three independent experiments with 
triplicate samples.
Cell cycle analysis
Flow cytometry analysis was used to analyze cell cycle distribution. After culture overnight, 
cells in 60 mm culture dishes were treated with culture medium containing 289.3 µM (IC50) 
of carboplatin and 0.086 µM (IC50) of gemcitabine, or in combination for 4 h. The drug 
administration schedules for the combinations were as followed: (i) 4 h gemcitabine 
followed by 4 h carboplatin; (ii) 0.5 h carboplatin followed by 3.5 h carboplatin plus 
gemcitabine. The time point when drug was added was considered to be 0 h. Three dishes 
from each group were collected at 24, 48 and 72 h, and fixed with 70% ethanol in −20°C for 
2 h. The cells were treated with 100 µg/ml RNase A at 37°C for 30 m to eliminate RNA and 
stained with 50 µg/ml propidium iodide at 4°C for 30 m. DNA histogram data was analyzed 
with a Stratedigm S1000 (Stratedigm Corporation, San Jose, CA, USA) and the list mode 
files were analyzed with WinMDI version 2.9.
Statistical analysis
The data from MTT assay were expressed as mean ± standard deviation (SD). The IC50 
values of carboplatin and gemcitabine and linear regression analyses were computed by 
GraphPad Prism 5 program (GraphPad Software Inc., San Diego, CA, USA). Dose-effect 
curve parameters, CI values, Fa-CI plot (plot representing CI versus Fa, the fraction affected 
by a particular dose) were calculated by CompuSyn program (Compusyn Inc, Paramus, NJ, 
USA). A p-value of <0.05 was denoted a statistically significant difference.
Results
Dose- and schedule-dependent cytotoxic effects of carboplatin/gemcitabine combination
The cytotoxic activities of carboplatin and gemcitabine were first determined individually on 
5637 cells. As expected, there was a dose-dependent cell killing effect. IC50 values ± SD 
were 289.3 ± 2.90 µM for carboplatin (Figure 1A) and 0.086 ± 0.008 µM for gemcitabine 
(Figure 1B).
The cytotoxicity of carboplatin/gemcitabine combination on 5637 cells was then evaluated 
using the CI method (16). Table II shows the dose-effect curve parameters (Dm and r) of the 
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two drugs either as single agents or in combination, as well as mean CI values of 
combinations in different treatment doses and schedules. The r values of 0.95 or above 
indicated good conformity of the dose-effect data with respect to the median-effect principle 
(16). The r values for all of the experiments were 0.99 or higher. Figure 1 C showed dose-
effect relationship of the two drugs combinations. The X axis represents the drug 
combination concentrations (µM); the Y axis (Fa) represents the ratio of the combination 
effect on inhibition of cell growth with Fa of 1.0 representing 100% cell killing. The 
horizontal dash line represents Fa of 0.5, or 50% cell killing. The antitumor activity of 
treatment with gemcitabine followed by carboplatin, or concurrent carboplatin and 
gemcitabine treatment was significantly better than that of carboplatin followed by 
gemcitabine. Figure 1 D showed plots of the combination indices for the interaction between 
the two drugs as a function of the treatment schedule. When 5637 cells were treated with 
gemcitabine for 4 h followed by carboplatin for 4 h, the Dm value was 127.16 ± 7.61 µM 
(Table II), slightly less than the calculated IC50 of the combination at 145.28 µM [(289.3 + 
0.086) ÷ 2]. That corresponded to the CI value of 0.88 ± 0.06, or slight synergism (Table I). 
Treatment of cells with carboplatin for 0.5 h followed by two drug combination for an 
additional 3.5 h had the Dm value of 119.03 ± 5.42 µM, corresponding to the CI value of 
0.82 ± 0.04, or moderate synergism. However, these two CI values were not statistically 
significant (p=0.19). As the concentration of carboplatin and gemcitabine combination 
increased, the CI value decreased (Table II). At the IC95 concentration, the CI values were 
0.44 ± 0.04 and 0.44 ± 0.02, respectively, indicating synergism. On the other hand, when 
5637 cells were treated with carboplatin for 4 h followed by gemcitabine for 4 h, the Dm 
value was 148.08 ± 3.39 µM, close to the calculated IC50 of 145.28 µM, which corresponded 
to the CI value of 1.02 ± 0.03, or nearly additive (Table II). This was less effective than the 
other two treatment schedules (p=0.017 and p=0.002, respectively). As the concentration of 
carboplatin and gemcitabine combination increased, the combined cytotoxic effects fell into 
moderate antagonism at IC95, much less effective than the treatments of gemcitabine 
followed by carboplatin or carboplatin followed by concurrent carboplatin/gemcitabine 
treatment (p<0.001) (Figure 1C).
Cell cycle analysis
It was next determined how carboplatin/gemcitabine combination changed cell cycle 
distribution, and affected the anti-tumor activity (Figure 2, Table III). The cell cycle 
distribution of untreated control cells did not change significantly except that the S phase 
slightly decreased at 72 h, possibly related to cell confluence and/or nutrition depletion. 
More carboplatin-treated cells were arrested at the S phase after 24 h of exposure (53.4%), 
and at the G2/M phase at the later time points (56.3% at 48 h and 52.6% at 72 h). The 
portion of cells with subdiploid DNA content (apoptosis) increased significantly at the 48 h 
and 72 h time points (15.3% and 19.5%, respectively). Gemcitabine-treated cells were 
arrested at the G0/G1 and early S phases (59.2%), with a parallel decrease of the population 
in G2/M phase at 24 h. At 48 and 72 h, more cells treated with gemcitabine had the 
subdiploid DNA content (15.1% and 15.9%, respectively) with the corresponding decrease 
of cells at G0/G1 phase, but the proportions of cells at the S and G2/M phases returned to 
those of the control cells. The cell cycle distribution patterns of cells treated with carboplatin 
and gemcitabine combinations, in either order, showed the combined effects of these two 
Wang et al. Page 4
Anticancer Res. Author manuscript; available in PMC 2015 September 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
medications. At 24 h after treatment, more cells were at the G0/G1 and early S phases 
(58.4% for cells treated with gemcitabine before carboplatin versus 56.6% for cells treated 
with carboplatin before carboplatin plus gemcitabine), similar to the cells treated with 
gemcitabine alone. At 48 h, more cells were arrested at the S phase (48.97% versus 52.44%, 
respectively). At 72 h, more cells were arrested at the late S and G2/M phases (38.1% versus 
33.7%, respectively), similar to the cells treated with carboplatin alone. More cells were at 
the sub-G0/G1 portion (34.3% versus 35.1%, respectively), suggesting synergistic or 
additive effect of the combination.
Discussion
This study found that, when 5637 cells were treated with carboplatin for 4 h followed by 
gemcitabine, the cytotoxic activity fell into additivity to antagonism range depending on the 
drug concentration relative to the IC50. On the other hand, when cancer cells were treated 
with gemcitabine followed by carboplatin, or carboplatin and gemcitabine simultaneously, 
additive to synergistic effects were observed. These findings are different from a previous 
study showing more synergistic effects when non-small cell lung cancer cells were treated 
with carboplatin followed by gemcitabine (7), but are consistent with another study showing 
that simultaneous treatment with carboplatin and gemcitabine exerted synergistic anti-tumor 
effect in canine osteosarcoma cell lines (10). These differences may be secondary to the fact 
that different cell lines were used in different studies. The current authors believe that the 
findings of the current study are more consistent with the underlying cell-killing 
mechanisms of these two drugs. As an alkylating agent, carboplatin kills cells mainly 
through induction of DNA adducts (17). Its cell killing is not cell cycle-specific. 
Gemcitabine is a nucleoside analog in which the hydrogen on the 2' carbon of deoxycytidine 
is replaced by a fluorine atom. During DNA replication, gemcitabine triphosphate replaces 
dCTP and is incorporated into the DNA strands that terminates DNA replication (18,19). 
Gemcitabine exhibits cell cycle specificity in that it primarily kills cells undergoing DNA 
synthesis (S-phase). It is hypothesized that treatment of carboplatin prior to gemcitabine 
induces DNA damage and arrests cell cycle that decreases the incorporation of gemcitabine 
triphosphate into DNA, and mitigates the cytotoxic effects of gemcitabine. The dose-
dependent antagonism is also observed. This suggests that, as more cells are arrested in their 
cell cycle with increased carboplatin concentration, less cytotoxicity with gemcitabine is 
observed. Treatment with carboplatin for 4 h is needed as it allows cells enough time to 
respond to DNA damage induced by carboplatin. No antagonism was seen when cells were 
treated with carboplatin for 0.5 h followed by carboplatin/gemcitabine concurrent treatment.
On the other hand, when cells were treated with gemcitabine followed by carboplatin or 
simultaneously with these two drugs, synergistic effects were observed (Table II and Figure 
1). Several mechanisms may contribute to the enhanced cytotoxicity of this combination. 
DNA structural changes by incorporation of gemcitabine favor the binding of cisplatin (20), 
and gemcitabine inhibits DNA repair of Pt-DNA adducts (21). Furthermore, platinum 
inhibits ribonucleotide reductase (22), and further enhances the incorporation of gemcitabine 
triphosphate into DNA. Nucleotide excision repair is the major pathway responsible for the 
removal of platinum-DNA adducts. Gemcitabine might reduce the effectiveness of 
nucleotide excision repair through its inhibition of ribonucleotide reductase (10).
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The cell cycle analysis of the current study showed that, around the concentration of IC50, 
cell cycle disturbance of carboplatin/gemcitabine combination was the combined effects of 
each individual drug. Treatment of gemcitabine arrested the cells at G1 and early S phase at 
24 h because of the termination of DNA replication. Treatment of carboplatin leads to the S 
phase arrest at an early time point (24 h), associated with reduced expression of cyclin E and 
cyclin B (23), and then G2/M phase blockage at 48 and 72 h, associated with CDC25C 
phosphorylation (24). The G2/M checkpoint allows for the repair of DNA damage occurred 
late in the S or G2 phase of cell cycle before mitosis. Because of the double insults, more 
cells underwent apoptosis (24,25), as it was observed that more cells were at the sub-G0/G1 
portion (Figure 2, Table III). The concentrations of these two drugs used in this study were 
at the corresponding IC50s. These findings were consistent with the current analysis with the 
CI method that showed near additive or slightly synergistic effect at the IC50 concentrations 
(Figure 1 and Table II).
The current findings may have significant clinical implication in the treatment for bladder 
cancer. The carboplatin-DNA adduct formation is essentially the same as that of cisplatin, 
even though a higher concentration of carboplatin is needed (17). Cisplatin is more 
commonly used in the treatment of bladder cancer. However, unlike carboplatin that is 
administered within one hour, cisplatin is given intravenously over several hours. If cisplatin 
is given before gemcitabine, arrest of cell cycle by cisplatin may affect the cytotoxic effect 
of gemcitabine. Further randomized clinical trials are needed to address this issue.
In conclusion, this study systemically analyzed the effects of doses and administration 
schedules of carboplatin/gemcitabine combination on the cytotoxic effects on a bladder 
cancer cell line. The analysis suggests that administration of gemcitabine before carboplatin 
or administration of these two drugs simultaneously is more effective than the schedule of 
carboplatin followed by gemcitabine.
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Figure 1. 
The anti-tumor activity of carboplatin, gemcitabine or in combination. A and B: Dose-
dependent cytotoxic effects of 5637 cells exposed to carboplatin (A) or gemcitabine (B). C. 
Dose-effect curves for the carboplatin/gemcitabine combinations. 5637 cells were treated 
with: gemcitabine for 4 h followed by carboplatin for 4 h (square); carboplatin for 0.5 h 
followed by carboplatin plus gemcitabine for 3.5 h (circle); carboplatin for 4 h followed by 
gemcitabine for 4 h (triangle). Data are means ± SD of three independent experiments (each 
with samples in triplicate). *p<0.05, ***p<0.001. D. CI Plot. CI values are plotted as a 
function of the fractional inhibition (Fa) from 0.10 to 0.97. The CI values of <0.9 (below the 
lower dash line), =0.9–1.1, and <1.1 (above the upper dash line) represent synergism, 
additivity and antagonism, respectively.
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Figure 2. 
Characteristic DNA histograms of 5637 cells treated with carboplatin, gemcitabine or in 
combination. The progressive cell cycle changes were observed after 24, 48 and 72 h of 
treatment, as compared with the untreated controls. Content of DNA is represented on the X 
axis; number of cells counted is represented on the Y axis.
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Table I
The classification of the combination index (CI) and anti-tumor activity. The CI value of between 0.9 and 1.1 
represent additivity. The CI value less than 0.9 represents synergism while the value above 1.1 means 
antagonism.
Synergism Antagonism
CI value Synergy category CI value Antagonism category
0.85–0.9 Slight synergy 1.1–1.2 Slight antagonism
0.7–0.85 Moderate synergy 1.2–1.45 Moderate antagonism
0.3–0.7 Synergy 1.45–3.3 antagonism
0.1–0.3 Strong synergy 3.3–10 Strong antagonism
<0.1 Very strong synergy >10 Very strong antagonism
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